Nephrologist 🇵🇭 • Internist • Flozinator • GN & Transplant • @uppghnephrology Alumni • @nephjc intern 2025-2026 @GlomCon Fellow 2023-2024 • @Neph_Sim 2021

Joined December 2020
332 Photos and videos
Pinned Tweet
15 Jul 2021
Kidney injury occuring in liver failure is a historical scenario imbued w/in the parlance of medicine for centuries. In this article, I try to discuss HRS— its current concepts & challenges. Thank you @Nephro_Sparks @DearbhlaKelly4 for helping me write this article!
Hepatorenal Syndrome: Current Concepts and Challenges by @msocoMD renalfellow.org/2021/07/15/h…
9
5
69
Marc Soco, MD retweeted
#TenPostNephJC #NephTwitter #NephJC 1/10 How often do we miss non-diabetic kidney disease (NDKD)? 🚩NDKD are 1) active urine sediment, 2) sudden worsening RFT, 3) absence of retinopathy 4) systemic symptoms like rash @Tiff_Caza kidney-international.org/art…
2
10
21
1,892
Marc Soco, MD retweeted
✨Exciting news #Nephtwitter The new #NephJC editorial interns are here! 📢 Give them a follow and make them feel at home nephjc.com/news/2025/6/21/ne… @DrBarbaTeba @AncaSt13 @dany_rcal @kiddo_kidney @AndrewDelaat @farahwehbe92 @rn_flex @assad_sm @ManoleaA @Nihal_Hamary
6
15
34
3,808
Marc Soco, MD retweeted
Hypertension control remains stubbornly low in underserved communities. IMPACTS‑BP asks whether a team‑based, multi‑component approach can meaningfully improve blood pressure control and adherence in low‑income patients 🎨#VisualAbstract by @DrAkshayaJ nephjc.com/news/2026/5/18/im…
1
21
25
2,457
Marc Soco, MD retweeted
1/10 #NephJC #TenPostNephJC. #NephTwitter In 2026 💊 FDA approved sparsentan for FSGS, an endothelin A/angiotensin II receptor inhibitor. Next up in the pipeline…transient receptor potential cation channel 6 (TRPC6) inhibitor (BI 764198) 🚰 Article 👇 pubmed.ncbi.nlm.nih.gov/4161…
2
10
19
1,769
Marc Soco, MD retweeted
Blessings abound! The Division received various awards during the recent convention: 1. One of the Most Outstanding Fellowship Training Institution in Adult Nephrology 2. 100% passing recent Board exams 3. One of the Best performing institution in test construction #TatakPGH
1
2
137
Marc Soco, MD retweeted
Hydralazine, a 1950s drug still used at the edges of modern care Cheap. Available. Signal of benefit… shadowed by decades of immune toxicity signals 58 min to #TenPostNephJC #NephJC pubmed.ncbi.nlm.nih.gov/6786…
10
17
1,805
Marc Soco, MD retweeted
Apr 18
Managing glomerular disease in tropical regions require a specialized lens. Join #GlomConPH on April 22, 2026, for a high-impact workshop designed for physicians to master the nuances of tropical nephrology—from biopsy interpretation to navigating the latest KDIGO updates.
3
6
657
Marc Soco, MD retweeted
B Cell Modulation in IgA Nephropathy 🏆 #IgAN #Nephpearls #Nephmadness Check out our review "IgA Nephropathy: An Overview of the Clinical Trials" by @ZohrehGh7 @haresh11 @NWiegley @Alexgr23 @rahaai @SaynaNorouzi @JEGAYTAN90 and the #Nephmadness write up by @LauraMarianiMD and @AleTomasiMD 👉 pubmed.ncbi.nlm.nih.gov/4105… 👉 @NephMadness ajkdblog.org/2026/03/01/neph…
1
24
48
3,334
Marc Soco, MD retweeted
0/10 Hey NephJC faithful, we are shaking it up. Given the 📉 attendance at live chats we’re changing to a summary 🧵& ❓ to answer, at your convenience. Still tag us #NephJC to get the discussion going! PS If we hear enough comments, we might bring chats back!😉
2
14
18
1,637
Marc Soco, MD retweeted
The IgAN Nephropathy curriculum provides a comprehensive review of the pathogenesis, treatment, and prediction of disease progression to help clinicians in their work. Access the new curriculum, supported by Otsuka: bit.ly/3PirS4N
3
18
63
3,291
Marc Soco, MD retweeted
#ISNWCN second HIT1 trial Semaglutide Improves Kidney Outcomes Regardless Of SGLT2i Use In People With Chronic Kidney Disease And Type 2 Diabetes: Post-hoc Analysis The Remodel Trial, by David Cherney
1
5
14
622
Marc Soco, MD retweeted
#ISNWCN First simultaneous publication comes from Hiddo Heerspink and ASSIST trial ✨ Phase II randomized crossover in IgAN on RASi SGLT2i. Atrasentan 0.75 mg reduced 24-h UPCR vs placebo. ETA blockade adds antiproteinuric effect on top of optimized therapy
2
11
21
883
Marc Soco, MD retweeted
What’s new in AKI/AKD KDIGO updates compared to KDIGO 2012. #ISNWCN
1
16
46
2,118
Marc Soco, MD retweeted
2/ @brian_rifkin 's recap highlighted our progress and future plans, but what stays with me is this: #nephjc never stops adapting. We keep learning, improving, and reaching for a better version of ourselves 🌟
1
4
10
942
Marc Soco, MD retweeted
1/ Today’s #nephjc graduation was pure joy. Seeing mentors and interns from around the world come together reminded me why this community matters. ✨Thank you for making it extraordinary @hswapnil @Nephro_Sparks @salinesalut @FravelShellie @meyyappannephro @roxnonna23
1
11
20
2,117
Marc Soco, MD retweeted
Delighted that FIND CKD has meet its primary endpoint. Fantastic news for patients with non-diabetic CKD, including those with GNs, including IgAN Thank you to Bayer, all the investigators, study teams & patients who have made FIND-CKD possible bayer.com/media/en-us/finere…
4
80
202
14,154
Marc Soco, MD retweeted
New terminology for iron deficiency in CKD ca. 2026 from @goKDIGO #Nephpearls Systemic iron deficiency (previously Absolute iron deficiency) ⬇️ Ferritin ⬇️ TSAT​ Iron-restricted erythropoiesis (previously Functional iron deficiency) ⬆️ Ferritin ⬇️ TSAT​ 👉 kdigo.org/guidelines/anemia-…
107
275
13,634